Compare · AVXL vs MTRI
AVXL vs MTRI
Side-by-side comparison of Anavex Life Sciences Corp. (AVXL) and Mentari Therapeutics Inc. (MTRI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AVXL focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MTRI focuses on Biotechnology: Pharmaceutical Preparations.
- MTRI is the larger of the two at $982.3M, about 11.4x AVXL ($86.2M).
- MTRI has been more active in the news (18 items in the past 4 weeks vs 7 for AVXL).
- AVXL has more recent analyst coverage (6 ratings vs 0 for MTRI).
- Company
- Anavex Life Sciences Corp.
- Mentari Therapeutics Inc.
- Price
- -
- -
- Market cap
- $86.2M
- $982.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 18
- Recent ratings
- 6
- 0
Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Mentari Therapeutics Inc.
The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Latest AVXL
- Director Velden Claus Vander was granted 50,000 stock options (SEC Form 4)
- Director Donhauser Peter D.O. was granted 50,000 stock options (SEC Form 4)
- President and CEO Kellmeyer Terrie was granted 200,000 stock options (SEC Form 4)
- Director Paeger Axel was granted 50,000 stock options (SEC Form 4)
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
- SEC Form 8-K filed by Anavex Life Sciences Corp.
- Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Latest MTRI
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13D filed by Mentari Therapeutics Inc.
- Officer Seurer Jerad G. was granted 257,000 stock options (SEC Form 4)
- Director Pernice Michelle Patricia was granted 37,000 stock options (SEC Form 4)
- Officer Divis Gregory J was granted 1,560,599 stock options (SEC Form 4)
- Director Bruno Julianne was granted 37,000 stock options (SEC Form 4)
- Officer Hagen Brett R was granted 171,000 stock options (SEC Form 4)
- Director Sandler Laura Lee was granted 37,000 stock options (SEC Form 4)
- Director Shegog Todd was granted 37,000 stock options (SEC Form 4)